Stephens Reaffirms Overweight Rating for Hologic (NASDAQ:HOLX)

Key Points

• Hologic's stock received an "overweight" rating from Stephens, with a price target of $78.00, implying a potential upside of 14.37%.
• Other analysts have raised their ratings on Hologic, with Citigroup upgrading to a "buy" and a target price increase to $80.00.
• The company's latest earnings report showed $1.08 EPS, surpassing estimates, and a revenue of $1.02 billion, reflecting a year-over-year growth of 1.2%.

Stephens reaffirmed their overweight rating on shares of Hologic (NASDAQ:HOLX - Free Report) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $78.00 price target on the medical equipment provider's stock.

Several other brokerages also recently commented on HOLX. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI upped their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. UBS Group upped their price objective on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Finally, Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Hologic has an average rating of "Moderate Buy" and an average target price of $79.38.

Hologic Stock Performance

HOLX stock traded up $0.78 during midday trading on Thursday, hitting $67.11. 768,267 shares of the company traded hands, compared to its average volume of 2,705,431. The stock has a market capitalization of $14.93 billion, a price-to-earnings ratio of 27.80, a price-to-earnings-growth ratio of 2.40 and a beta of 0.57. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The business has a 50 day simple moving average of $66.47 and a 200-day simple moving average of $62.75.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business earned $1.06 earnings per share. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts predict that Hologic will post 4.28 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Chung Wu Investment Group LLC bought a new stake in shares of Hologic during the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 273 shares during the last quarter. Loomis Sayles & Co. L P purchased a new position in Hologic during the second quarter valued at $33,000. Zions Bancorporation National Association UT bought a new position in shares of Hologic in the 1st quarter worth $34,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 436 shares during the period. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.